Med. praxi. 2016;13(1):26-29 | DOI: 10.36290/med.2016.005

LADY and MODY: How do we know them?

doc.MUDr.Zdeněk Šumník, Ph.D., doc.MUDr.Štěpánka Průhová, Ph.D.
Pediatrická klinika 2. LF UK a FN v Motole, Praha

LADA and MODY are frequently occurring forms of diabetes of different etiology, treatment and prognosis, that may share some

common clinical characteristics. This article highlights the importance of correct etiological diagnostic as a key prerequisite for a

disease-tailored treatment and improvement of diabetes control.

Keywords: diabetes, LADA, MODY

Published: March 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šumník Z, Průhová Š. LADY and MODY: How do we know them? Med. praxi. 2016;13(1):26-29. doi: 10.36290/med.2016.005.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2015; 38: S8-S17. Go to original source... Go to PubMed...
    2. Eisenbarth GS. Update in type 1 diabetes. J Clin Endocrinol Metab 2007; 92(7): 2403-2407. Go to original source... Go to PubMed...
    3. Petruzelkova L, Ananieva-Jordanova R, Vcelakova J, et al. The dynamic changes of zinc transporter 8 autoantibodies in Czech children from the onset of Type 1 diabetes mellitus. Diabet Med 2014; 31(2): 165-171. Go to original source... Go to PubMed...
    4. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309(23): 2473-2479. Go to original source... Go to PubMed...
    5. Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009; 94(12): 4635-4644. Go to original source... Go to PubMed...
    6. Groop L, Tuomi T, Rowley M, Zimmet P, Mackay IR. Latent autoimmune diabetes in adults (LADA)--more than a name. Diabetologia 2006; 49(9): 1996-1998 Go to original source... Go to PubMed...
    7. Ellard S, Bellanne-Chantelot C, Hattersley AT. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008; 51: 546-553. Go to original source... Go to PubMed...
    8. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic ?-cell diabetes. Nat Clin Pract Endocrinol Metab 2008; 4: 200-213. Go to original source... Go to PubMed...
    9. Ellard S, Beards F, Allen L, et al. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. Diabetologia 2000; 43: 250-253. Go to original source... Go to PubMed...
    10. Colom C, Corcoy R Maturity onset diabetes of the young and pregnancy. Best Pract Res Clin Endocrinol Metab 2010; 24: 605-615. Go to original source... Go to PubMed...
    11. Lebl J, Koloušková S, Dušátková P, et al. Játra, ledviny a diabetes: tři tváře deficitu genu HNF1B. Vnitr Lek 2014; 60: 725-9. Go to PubMed...
    12. Steele A, Shields BM, Shepherd M, et al. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med 2010; 27: 157-161. Go to original source... Go to PubMed...
    13. Průhová Š, Dušátková P, Neumann D, et al. Two Cases of Diabetic Ketoacidosis in HNF1A-MODY Linked to Severe Dehydration: Is it time to change the diagnostic criteria for MODY? Diabetes Care 2013; 36: 2573-2574. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.